These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4936883)

  • 21. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.
    Mortimer CH; Tunbridge WM; Carr D; Yeomans L; Lind T; Coy DH; Bloom SR; Kastin A; Mallinson CN; Besser GM; Schally AV; Hall R
    Lancet; 1974 Apr; 1(7860):697-701. PubMed ID: 4132421
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma glucagon and insulin concentrations in acromegaly.
    Trimble ER; Atkinson AB; Buchanan KD; Hadden DR
    J Clin Endocrinol Metab; 1980 Sep; 51(3):626-31. PubMed ID: 6997331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of estrogen therapy on carbohydrate metabolism in acromegaly.
    Mintz DH; Finster JL; Josimovich JB
    J Clin Endocrinol Metab; 1967 Sep; 27(9):1321-7. PubMed ID: 4292250
    [No Abstract]   [Full Text] [Related]  

  • 26. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly.
    Hattori N; Shimatsu A; Kato Y; Koshiyama H; Ishikawa Y; Assadian H; Tanoh T; Nagao M; Imura H
    J Clin Endocrinol Metab; 1990 Mar; 70(3):771-6. PubMed ID: 2106529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum growth hormone and prolactin response to thyrotropin-releasing hormone in patients with acromegaly before and after surgery.
    Samaan NA; Leavens ME; Jesse RH
    J Clin Endocrinol Metab; 1974 Jun; 38(6):957-63. PubMed ID: 4208807
    [No Abstract]   [Full Text] [Related]  

  • 28. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Childhood acromegaly: successful therapy with conventional radiation and effects of chlorpromazine on growth hormone and prolactin secretion.
    AvRuskin TW; Sau K; Tang S; Juan C
    J Clin Endocrinol Metab; 1973 Sep; 37(3):380-8. PubMed ID: 4206490
    [No Abstract]   [Full Text] [Related]  

  • 30. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [STH blood level after metopirone in 12 patients with acromegaly].
    Chiodini PG; Liuzzi A; Spinelli F; Botalla L; Silvestrini F
    Ann Endocrinol (Paris); 1972; 33(4):431-5. PubMed ID: 4664004
    [No Abstract]   [Full Text] [Related]  

  • 32. Evidence for higher proportion of "little" growth hormone with increased radioreceptor activity in acromegalic plasma.
    Gorden P; Lesniak MA; Eastman R; Hendricks CM; Roth J
    J Clin Endocrinol Metab; 1976 Aug; 43(2):364-73. PubMed ID: 950368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Growth hormone: interpretation of the test results].
    Kato Y; Imura H
    Nihon Rinsho; 1969 Mar; ():Suppl:958-68. PubMed ID: 4948305
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.
    Yen SS; Siler TM; DeVane GW
    N Engl J Med; 1974 Apr; 290(17):935-8. PubMed ID: 4593614
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma growth hormone response to thyrotropin-releasing hormone in patients with active acromegaly.
    Faglia G; Beck-Peccoz P; Ferrari C; Travaglini P; Ambrosi B; Spada A
    J Clin Endocrinol Metab; 1973 Jun; 36(6):1259-62. PubMed ID: 4196265
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of acromegaly using CB-154 and medroxy-progesterone acetate].
    Ichikawa Y; Yoshida K; Kawagoe M
    Horumon To Rinsho; 1977 Dec; 25(12):1303-4. PubMed ID: 598028
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of dexamethasone on plasma growth hormone levels in acromegaly.
    Nakagawa K; Horiuchi Y; Mashimo K
    J Clin Endocrinol Metab; 1970 Nov; 31(5):502-6. PubMed ID: 4919042
    [No Abstract]   [Full Text] [Related]  

  • 38. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secretin and insulin release in acromegaly.
    Chisholm DJ; Lazarus L; Young JD
    J Clin Endocrinol Metab; 1972 Jul; 35(1):108-12. PubMed ID: 5032508
    [No Abstract]   [Full Text] [Related]  

  • 40. [Permanent and non-suppressable somatotropic hypersecretion in acromegaly].
    Strauch G; Modigliani E; Bricaire H
    Presse Med (1893); 1970 Jan; 78(4):167-70. PubMed ID: 4907364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.